In this issue of Blood, Liyanage et al demonstrate that acute myeloid leukemia (AML) cells exhibit increased mitochondrial DNA (mtDNA) content and that the 29,39-dideoxycytidine (ddC; an inhibitor of mtDNA biosynthesis already used in clinic) selectively kills leukemia cells.
A mitochondrial drug to treat AML
Pinton, Paolo
Primo
2017
Abstract
In this issue of Blood, Liyanage et al demonstrate that acute myeloid leukemia (AML) cells exhibit increased mitochondrial DNA (mtDNA) content and that the 29,39-dideoxycytidine (ddC; an inhibitor of mtDNA biosynthesis already used in clinic) selectively kills leukemia cells.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
223.pdf
solo gestori archivio
Descrizione: Full text editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
736.22 kB
Formato
Adobe PDF
|
736.22 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
